A phase II, multicenter study to determine the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma

×

Error message

  • Notice: Trying to access array offset on value of type null in bootstrap_pager() (line 53 of /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
  • Notice: Trying to access array offset on value of type null in bootstrap_pager() (line 95 of /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
Study title: 
A phase II, multicenter study to determine the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma
Long title: 
A phase II, multicenter study to determine the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma
Date receipt dossier: 
29 Nov 2018
EU record number: 
bb2121-MM-001
EudraCT number: 
2017-002245-29
Pharmaceutical study code: 
bb2121
Company / Sponsor: 
Celgene
Phase: 
II
Treated organism: 
Humans
Indication category: 
Cancer therapy
Disease: 
relapsed and refractory multiple myeloma
Therapeutic approach: 
Immunotherapy
Genetic modification: 
BCMA02 (human B cell maturation antigen)-CAR
Method of transfer of nucleic acid of interest: 
Lentiviral vectors
Administered biological material: 
Autologous T-cells transduced with lentiviral vectors expressing BCMA02 (human B cell maturation antigen) CAR
Route of administration: 
Intravenous
Locations in Belgium: 
UZ Leuven
Type of procedure: 
Contained use only
Current status: 
Authorized